These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 27738804

  • 1. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R, Johansson M, Alamdari F, Sidiki A, Holmström B, Hansson J, Vasko J, Marits P, Gabrielsson S, Riklund K, Winqvist O, Sherif A.
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [Abstract] [Full Text] [Related]

  • 2. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy.
    Alvaeus J, Rosenblatt R, Johansson M, Alamdari F, Jakubczyk T, Holmström B, Hemdan T, Huge Y, Aljabery F, Gabrielsson S, Riklund K, Winqvist O, Sherif A.
    World J Urol; 2020 Sep; 38(9):2207-2213. PubMed ID: 31760442
    [Abstract] [Full Text] [Related]

  • 3. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F.
    J Clin Oncol; 2018 Dec 01; 36(34):3353-3360. PubMed ID: 30343614
    [Abstract] [Full Text] [Related]

  • 4. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU, Nordic Urothelial Cancer Group.
    Eur Urol; 2012 Jun 01; 61(6):1229-38. PubMed ID: 22189383
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B, Li H, Zhang C, Yang K, Qiao B, Zhang Z, Xu Y.
    Eur J Surg Oncol; 2013 Oct 01; 39(10):1150-6. PubMed ID: 23721764
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW, Lim SH, Kwon GY, Kim CK, Park W, Pyo H, Chung JH, Song W, Sung HH, Jeong BC, Park SH.
    Cancer Res Treat; 2024 Jul 01; 56(3):893-897. PubMed ID: 38374699
    [Abstract] [Full Text] [Related]

  • 11. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.
    Eur Urol; 2019 Feb 01; 75(2):231-239. PubMed ID: 30290956
    [Abstract] [Full Text] [Related]

  • 12. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    van Hoogstraten LMC, van Gennep EJ, Kiemeney LALM, Witjes JA, Voskuilen CS, Deelen M, Mertens LS, Meijer RP, Boormans JL, Robbrecht DGJ, Beerepoot LV, Verhoeven RHA, Ripping TM, BlaZIB Study Group, van Rhijn BWG, Aben KKH, Hermans TJN.
    World J Urol; 2022 Jan 01; 40(1):111-118. PubMed ID: 34585294
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Mansour AM, Soloway MS, Eldefrawy A, Singal R, Joshi S, Manoharan M.
    Can J Urol; 2015 Apr 01; 22(2):7690-7. PubMed ID: 25891331
    [Abstract] [Full Text] [Related]

  • 14. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES.
    Anticancer Res; 2016 Feb 01; 36(2):495-501. PubMed ID: 26851002
    [Abstract] [Full Text] [Related]

  • 15. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB.
    Eur Urol Focus; 2018 Sep 01; 4(5):720-724. PubMed ID: 28753837
    [Abstract] [Full Text] [Related]

  • 16. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
    Granfors T, Tomic R, Ljungberg B.
    Scand J Urol Nephrol; 2009 Sep 01; 43(4):293-9. PubMed ID: 19363744
    [Abstract] [Full Text] [Related]

  • 17. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
    Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW.
    BJU Int; 2014 Jul 01; 114(1):67-74. PubMed ID: 24053889
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A.
    Eur Urol Oncol; 2024 Jun 01; 7(3):614-624. PubMed ID: 38184473
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
    Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI.
    Urol Oncol; 2015 Sep 01; 33(9):386.e1-6. PubMed ID: 26122712
    [Abstract] [Full Text] [Related]

  • 20. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S.
    Eur J Surg Oncol; 2009 Apr 01; 35(4):352-5. PubMed ID: 18722076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.